TXG stock forecast, quote, news & analysis
10x Genomics Inc is a life science technology company based in the United States... Show more
Why 10x Genomics (TXG) Stock Is Up +35.7% in the Last 30 Days
Key Takeaways
- 10x Genomics (TXG) shares climbed roughly 35.7% over the trailing 30 days, rising from a closing price of $47.05 to about $63.87.
- The advance was powered by a stronger-than-expected Q2 2026 report, an upward revision to full-year revenue guidance, and early enthusiasm for the new Atera spatial biology platform.
- Management raised its 2026 revenue outlook to $610–$630 million and pointed to AI-driven demand for biological data as a structural tailwind.
- The broader quarter reflects a multi-month re-rating built on product innovation, the Proteintech Genomics acquisition, and high-profile research collaborations.
10x Genomics (TXG) Company Overview and Market Position
10x Genomics is a life-science technology company that designs and sells instruments, consumables, and software used to analyze biological systems at single-cell and spatial resolution. Its core platforms — Chromium for single-cell analysis and the Visium and Xenium spatial products — help researchers measure gene expression, epigenetics, and protein activity across large-scale experiments.
The company competes in the fast-growing single-cell and spatial biology segment of the life-science tools market, serving academic institutions, academic medical centers, and biopharmaceutical companies. Investors follow TXG closely because of its recurring consumables revenue model, its leading position in high-resolution biological analysis, and its exposure to the growing use of AI in drug discovery and biological research.
10x Genomics (TXG) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, TXG advanced from a closing price of $47.05 on July 22, 2026, to roughly $63.87, a gain of about $16.82, or approximately 35.7%. The move marked a decisive breakout after the stock traded in the mid-to-high $40s through much of July.
The quarterly picture is even stronger. As of early August, TXG had risen more than 110% over the trailing three months, extending a broader recovery from a 52-week low of $11.16. The multi-month uptrend reflects improving demand fundamentals and a shift in investor sentiment toward life-science tools, rather than a single isolated event.
What Drove TXG Stock Price in the Last 30 Days
The sharpest catalyst arrived in early August, when 10x Genomics reported second-quarter 2026 results that beat expectations. Revenue came in at $151 million versus a consensus estimate near $146.5 million, while the adjusted loss of $0.14 per share was narrower than the roughly $0.24 loss analysts had projected. On a reported basis, revenue fell about 12.6% year over year, but excluding non-recurring settlement revenue, revenue rose 3%.
Management simultaneously raised its full-year 2026 revenue guidance to a range of $610 million to $630 million, up from $600 million to $625 million. The higher outlook was anchored by strong early demand for Atera, the company's next-generation spatial whole-transcriptome platform. Booked Atera orders by the end of the quarter already exceeded the roughly 40 systems the company expects to ship in 2026, with shipments limited by manufacturing capacity rather than demand.
The period also featured the acquisition of Proteintech Genomics, which expanded 10x Genomics' proteomics and multi-omics capabilities, and a strategic research collaboration with the Cleveland Clinic. Gross margin improved to 74%, cash and marketable securities rose to about $552 million, and the company ended the quarter with no debt. These factors, combined with growing investor attention on AI-driven biological research, helped sustain the rally.
What Drove TXG Stock Performance Over the Last Quarter
The quarterly advance reflects a broader narrative shift rather than any single headline. The launch of Atera earlier in the year, unveiled at the AACR Annual Meeting 2026, positioned 10x Genomics to expand its spatial biology opportunity and its total addressable market. Early commitments from global service providers and AI-focused research programs reinforced confidence in the platform's commercial potential.
Underlying this momentum is a change in the academic funding environment that has weighed on life-science tools for several years. Improving research funding dynamics, coupled with rising demand for high-quality single-cell and spatial data to train AI models, has supported a recovery in sentiment. The Proteintech Genomics acquisition and the Cleveland Clinic collaboration broadened the company's multi-omics and translational research reach, while a beat-and-raise earnings report gave investors fresh evidence of improving fundamentals.
Trending AI Robots
For traders seeking a systematic way to track momentum across thousands of equities, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading bots. Tickeron hosts hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. These bots vary in strategy, timeframe, and performance metrics, giving users a way to explore different approaches to automated trading and market analysis. The page is designed to help investors discover tools that align with their own research process and trading style.
TXG Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape TXG's trajectory in the coming quarters. The pace of Atera instrument shipments — heavily weighted toward the fourth quarter — will be a central focus, as will the platform's consumables pull-through once systems are installed in customer labs. Management has signaled a modest sequential revenue decline in the third quarter as customers defer purchases of existing Xenium and Visium products ahead of the Atera transition.
Investors should also monitor the academic funding environment, which remains a key demand driver, as well as competitive developments in spatial and single-cell biology. AI-related demand for large-scale biological datasets, continued adoption of the Flex Apex assay, and the integration of Proteintech Genomics' protein-analysis capabilities represent additional catalysts. Persistent operating losses and the execution risk around manufacturing ramp-up remain the primary considerations for the stock's outlook.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TXG's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for TXG turned positive on August 10, 2026. Looking at past instances where TXG's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 07, 2026. You may want to consider a long position or call options on TXG as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TXG advanced for three days, in of 275 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 216 cases where TXG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TXG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
TXG broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.277) is normal, around the industry mean (7.636). TXG has a moderately low P/E Ratio (0.000) as compared to the industry average of (46.808). TXG's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.725). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. P/S Ratio (13.477) is also within normal values, averaging (6.463).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a life science technology company, which engages in building products to interrogate, understand and master biology
Industry ServicestotheHealthIndustry